YH14755 + Metformin + Rosuvastatin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemia
Conditions
Dyslipidemia, Type II Diabetes
Trial Timeline
Nov 4, 2015 → Jul 7, 2017
NCT ID
NCT02586129About YH14755 + Metformin + Rosuvastatin
YH14755 + Metformin + Rosuvastatin is a phase 3 stage product being developed by Yuhan for Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02586129. Target conditions include Dyslipidemia, Type II Diabetes.
What happened to similar drugs?
15 of 20 similar drugs in Dyslipidemia were approved
Approved (15) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02586129 | Phase 3 | Completed |
Competing Products
20 competing products in Dyslipidemia